# A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

> **NCT04255433** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 13299 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT04255433
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-29
- **Primary completion:** 2025-06-12
- **Final completion:** 2025-06-12
- **Target enrollment:** 13299 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04255433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04255433, "A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT04255433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*